Recursion Pharmaceuticals (RXRX) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vir Biotechnology (VIR) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 103.5% versus a loss of 18.4%. Over five years, VIR leads with a -70.5% price change compared with -77.6% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($2.09 billion vs $1.82 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXRX | VIR |
|---|---|---|
| Share price | $3.90 | $10.78 |
| Market cap | $2.09B | $1.82B |
| 1-day change | -8.78% | -6.42% |
| YTD return | +4.40% | +91.04% |
| 1-year return | -18.36% | +103.53% |
| 5-year return | -77.57% | -70.53% |
| EPS (TTM) | $-1.00 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $11.94 |
| 52-week low | $2.77 | $4.82 |
| Distance from 52-week high | -45.75% | -9.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +85.37% | +92.76% |
| Average volume | 20.56M | 1.90M |
| Shares outstanding | 535.34M | 169.22M |
| Employees | 600 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed RXRX by 121.9 percentage points over the past year.
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
RXRX vs VIR FAQ
Which is bigger, Recursion Pharmaceuticals or Vir Biotechnology?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.09B compared with $1.82B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, RXRX or VIR?
VIR returned +103.53% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Recursion Pharmaceuticals and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.